Compare SIM & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIM | ABCL |
|---|---|---|
| Founded | 1969 | 2012 |
| Country | Mexico | Canada |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.1B |
| IPO Year | 2002 | 2020 |
| Metric | SIM | ABCL |
|---|---|---|
| Price | $22.03 | $9.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $18.69 |
| AVG Volume (30 Days) | 1.1K | ★ 2.8M |
| Earning Date | 10-28-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $75,128,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.74 |
| P/E Ratio | $32.88 | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $23.16 | $2.75 |
| 52 Week High | $34.35 | $14.98 |
| Indicator | SIM | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 31.60 | 33.61 |
| Support Level | N/A | $3.45 |
| Resistance Level | $27.56 | $12.91 |
| Average True Range (ATR) | 0.65 | 0.84 |
| MACD | -0.48 | -0.22 |
| Stochastic Oscillator | 0.00 | 1.84 |
Grupo Simec SAB de CV is a diversified producer, processor and distributor of SBQ steel and structural steel products with production and commercial operations. The group's SBQ products are used across a range of engineered end-user applications, including axles, hubs, and crankshafts for automobiles and light trucks, machine tools, and off-highway equipment. Its structural steel products are used in the non-residential construction market and other construction applications. Its segments are Mexico, Brazil, and the United States of America. The maximum of its sales is from the Mexico segment.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.